{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:27:20Z","timestamp":1787826440370,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.092","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T11:30:18Z","timestamp":1511263818000},"page":"7070-7076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Controlled human infections"],"prefix":"10.1016","volume":"35","author":[{"given":"Meta","family":"Roestenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Yazdanbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.092_b0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S0022172400001856","article-title":"Recent researches concerning the Etiology, Propagation, and Prevention of Yellow Fever, by the United States Army Commission","volume":"2","author":"Reed","year":"1902","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2017.10.092_b0010","first-page":"1747","article-title":"Experimental investigations regarding the etiology of dengue fever. 1907","volume":"189","author":"Ashburn","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/clinids\/8.1.157","article-title":"The Willowbrook hepatitis studies revisited: ethical aspects","volume":"8","author":"Krugman","year":"1986","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0020","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(03)15111-2","article-title":"Benjamin Jesty: new light in the dawn of vaccination","volume":"362","author":"Pead","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.10.092_b0025","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1086\/322664","article-title":"The ethical challenge of infection-inducing challenge experiments","volume":"33","author":"Miller","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/QCO.0000000000000002","article-title":"The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review","volume":"26","author":"Epstein","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri2902","article-title":"Experimental human challenge infections can accelerate clinical malaria vaccine development","volume":"11","author":"Sauerwein","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.10.092_b0040","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.092_b0045","doi-asserted-by":"crossref","unstructured":"Teirlinck AC, Roestenberg M, van d V, Scholzen A, Heinrichs MJ, Siebelink-Stoter R, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis 2013;207: 656\u201360.","DOI":"10.1093\/infdis\/jis725"},{"key":"10.1016\/j.vaccine.2017.10.092_b0050","doi-asserted-by":"crossref","unstructured":"Arevalo-Herrera M, Forero-Pena DA, Rubiano K, Gomez-Hincapie J, Martinez NL, Lopez-Perez M, et al., Plasmodium vivax Sporozoite Challenge in Malaria-Naive and Semi-Immune Colombian Volunteers. PLoS One 2014;9: e99754.","DOI":"10.1371\/journal.pone.0099754"},{"key":"10.1016\/j.vaccine.2017.10.092_b0055","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fmicb.2014.00686","article-title":"Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection","volume":"5","author":"Hodgson","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2017.10.092_b0060","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.14-0119","article-title":"Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites","author":"Shekalaghe","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.10.092_b0065","unstructured":"U.S.Food and Drug Administration. FDA approval of VAXCHORA, <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm508903.htm>; 27-12-2016 [accessed 6-7-2017]."},{"key":"10.1016\/j.vaccine.2017.10.092_b0070","unstructured":"News on Zikavirus challenge model, http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/25\/468120804\/why-scientists-hope-to-inject-some-people-with-zika-virus, https:\/\/www.statnews.com\/2017\/02\/28\/zika-vaccine-ethics-panel\/; 25-2-2017 [accessed 30-10-2017]."},{"key":"10.1016\/j.vaccine.2017.10.092_b0075","unstructured":"WHO. WHO pneumonia fact sheet, <http:\/\/www.who.int\/mediacentre\/factsheets\/fs331\/en\/>; 1-9-2016 [accessed 6-7-2017]."},{"key":"10.1016\/j.vaccine.2017.10.092_b0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tim.2011.06.003","article-title":"Experimental human pneumococcal carriage models for vaccine research","volume":"19","author":"Ferreira","year":"2011","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2017.10.092_b0085","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1164\/rccm.201503-0542OC","article-title":"First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial","volume":"192","author":"Collins","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2017.10.092_b0090","doi-asserted-by":"crossref","unstructured":"Wright AK, Bangert M, Gritzfeld JF, Ferreira DM, Jambo KC, Wright AD, et al., Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. PLoS Pathog 2013;9: e1003274.","DOI":"10.1371\/journal.ppat.1003274"},{"key":"10.1016\/j.vaccine.2017.10.092_b0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/mi.2015.35","article-title":"Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage","volume":"9","author":"Glennie","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2017.10.092_b0100","unstructured":"WHO. Dengue fact sheet, <http:\/\/www.who.int\/mediacentre\/factsheets\/fs117\/en\/>; 6-7-2017 [accessed 6-7-2017]."},{"key":"10.1016\/j.vaccine.2017.10.092_b0105","unstructured":"Dengue vaccine initiative. Live attenuated dengue vaccines, <http:\/\/www.denguevaccines.org\/live-attenuated-vaccines>; 6-7-2016 [accessed 6-7-2017]."},{"key":"10.1016\/j.vaccine.2017.10.092_b0110","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1016\/j.vaccine.2015.09.052","article-title":"Dengue human infection models to advance dengue vaccine development","volume":"33","author":"Larsen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.092_b0115","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/cid\/ciu078","article-title":"An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution","volume":"58","author":"Waddington","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0120","doi-asserted-by":"crossref","unstructured":"Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, et al., Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with Placebo and Ty21a. PLoS Negl Trop Dis 2016; 10: e0004926.","DOI":"10.1371\/journal.pntd.0004926"},{"key":"10.1016\/j.vaccine.2017.10.092_b0125","doi-asserted-by":"crossref","first-page":"e007481","DOI":"10.1136\/bmjopen-2014-007481","article-title":"Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers","volume":"5","author":"McCullagh","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2017.10.092_b0130","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cid\/cix042","article-title":"Evaluation of the clinical and microbiological response to salmonella Paratyphi A infection in the first paratyphoid human challenge model","volume":"64","author":"Dobinson","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12967-016-0819-7","article-title":"Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans","volume":"14","author":"Fresnay","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.vaccine.2017.10.092_b0140","unstructured":"WHO. WHO estimates of the global burden of foodborne diseases, <http:\/\/www.who.int\/foodsafety\/publications\/foodborne_disease\/fergreport\/en\/>; 3-12-2015 [accessed 6-7-2017]."},{"key":"10.1016\/j.vaccine.2017.10.092_b0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1084\/jem.86.5.409","article-title":"Transmission of epidemic gastroenteritis to human volunteers by oral administration of fecal filtrates","volume":"86","author":"Gordon","year":"1947","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.10.092_b0150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM197707142970204","article-title":"Clinical immunity in acute gastroenteritis caused by Norwalk agent","volume":"297","author":"Parrino","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.092_b0155","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/infdis\/129.6.709","article-title":"Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers","volume":"129","author":"Wyatt","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/infdis\/123.3.307","article-title":"Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates","volume":"123","author":"Dolin","year":"1971","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0165","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0016-5085(19)30507-4","article-title":"Bismuth subsalicylate therapy of viral gastroenteritis","volume":"78","author":"Steinhoff","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2017.10.092_b0170","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/CVI.00196-15","article-title":"Serological correlates of protection against a GII.4 Norovirus","volume":"22","author":"Atmar","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.10.092_b0175","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.10.092_b0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0185","doi-asserted-by":"crossref","unstructured":"Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, et al., Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One 2013;8: e62778.","DOI":"10.1371\/journal.pone.0062778"},{"key":"10.1016\/j.vaccine.2017.10.092_b0190","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2009.02.061","article-title":"DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial","volume":"27","author":"Jones","year":"2009","journal-title":"Vaccine"},{"issue":"388","key":"10.1016\/j.vaccine.2017.10.092_b0195","first-page":"1603","article-title":"DALYs and HALE Collaborators, Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"2016","author":"GBD","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.10.092_b0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/QCO.0b013e328358993a","article-title":"Human soil-transmitted helminths: implications of mass drug administration","volume":"25","author":"Vercruysse","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.092_b0205","doi-asserted-by":"crossref","unstructured":"Hotez PJ, Pecoul B, Rijal S, Boehme C, Aksoy S, Malecela M, et al., Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies. PLoS Negl Trop Dis 2016;10: e0003895.","DOI":"10.1371\/journal.pntd.0003895"},{"key":"10.1016\/j.vaccine.2017.10.092_b0210","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","article-title":"Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease","volume":"135","author":"Croese","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.10.092_b0215","doi-asserted-by":"crossref","unstructured":"McSorley HJ, Gaze S, Daveson J, Jones D, Anderson RP, Clouston A, et al., Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One 2011;6: e24092.","DOI":"10.1371\/journal.pone.0024092"},{"key":"10.1016\/j.vaccine.2017.10.092_b0220","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1365-2222.2009.03187.x","article-title":"Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study","volume":"39","author":"Feary","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.vaccine.2017.10.092_b0225","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2222.2009.03433.x","article-title":"Experimental hookworm infection: a randomized placebo-controlled trial in asthma","volume":"40","author":"Feary","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.vaccine.2017.10.092_b0230","doi-asserted-by":"crossref","unstructured":"Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, et al., Effect of hookworm infection on wheat challenge in celiac disease\u2013a randomised double-blinded placebo controlled trial. PLoS One 2011;6: e17366.","DOI":"10.1371\/journal.pone.0017366"},{"key":"10.1016\/j.vaccine.2017.10.092_b0235","doi-asserted-by":"crossref","first-page":"13797","DOI":"10.1038\/srep13797","article-title":"Experimental hookworm infection and escalating gluten challenges are associated with increased microbial richness in celiac subjects","volume":"5","author":"Giacomin","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.10.092_b0240","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13071-015-0857-7","article-title":"Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes","volume":"8","author":"Corstjens","year":"2015","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2017.10.092_b0245","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM199503303321304","article-title":"The infectivity of Cryptosporidium parvum in healthy volunteers","volume":"332","author":"DuPont","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.092_b0250","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T08:07:24Z","timestamp":1706256444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17315219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":50,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17315219"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.092","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled human infections","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}